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Autologous Blood and Platelet-Rich Plasma Injections  
in the Treatment of Achilles Tendinopathy:  
A Critically Appraised Topic
Cori Sinnott, Hayley M. White, Jennifer W. Cuchna, and Bonnie L. Van Lunen
Clinical Scenario: Achilles tendinopathy is a painful condition commonly affecting the general and athletic population. It 
presents with localized pain, stiffness, and swelling in the midportion of the Achilles tendon. The physical stress placed on 
the tendon results in microtrauma, which leads to subsequent inflammation and degeneration. While it is not surprising that 
this condition affects the physically active, nearly one-third of Achilles tendinopathy cases occur in sedentary individuals. 
Etiology for this condition stems from a change in loading patterns and/or overuse of the tendon, resulting in microscopic 
tearing and degenerative changes. There are numerous causes contributing to the maladaptive response in these patients, 
such as mechanical, age-related, genetic, and vascular factors. The treatment for these patients is typically load manage-
ment and eccentric strengthening of the gastrocnemius–soleus complex. Unfortunately, conservative treatment can lead 
to surgical intervention in up to 45% of cases. A relatively new phenomenon in the treatment of this condition is the use 
of autologous blood injections (ABI) and platelet-rich plasma injections (PRPI). This need for a less invasive treatment 
fostered more investigation into ABI and PRPI to treat these nonresponsive patients. However, the evidence concerning 
the effectiveness of these treatments in patients with Achilles tendinopathy has not been synthesized. Focused Clinical 
Question: In patients with Achilles tendinopathy, how do variations of ABI and PRPI compared with a placebo and/or 
eccentric training affect pain and function?
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Clinical Scenario
Achilles tendinopathy is a painful condition commonly 
affecting the general and athletic population.1,2 It presents 
with localized pain, stiffness, and swelling in the midpor-
tion of the Achilles tendon.3 The physical stress placed 
on the tendon results in microtrauma, which leads to sub-
sequent inflammation and degeneration.4 While it is not 
surprising that this condition affects the physically active, 
nearly one-third of Achilles tendinopathy cases occur in 
sedentary individuals.2 Etiology for this condition stems 
from a change in loading patterns and/or overuse of the 
tendon, resulting in microscopic tearing and degenera-
tive changes.5 There are numerous causes contributing 
to the maladaptive response in these patients, such as 
mechanical, age-related, genetic, and vascular factors.6 
The treatment for these patients is typically load manage-
ment and eccentric strengthening of the gastrocnemius–
soleus complex. Unfortunately, conservative treatment 
can lead to surgical intervention in up to 45% of cases.7 
A relatively new phenomenon in the treatment of this 
condition is the use of autologous blood injections (ABI) 
and platelet-rich plasma injections (PRPI). This need 
for a less invasive treatment fostered more investigation 
into ABI and PRPI to treat these nonresponsive patients. 
However, the evidence concerning the effectiveness of 
these treatments in patients with Achilles tendinopathy 
has not been synthesized.
Focused Clinical Question
In patients with Achilles tendinopathy, how do varia-
tions of ABI and PRPI compared with a placebo and/or 
eccentric training affect pain and function?
Summary of Search, “Best 
Evidence” Appraised, and Key 
Findings:
• The literature was searched for studies of level 2 
evidence (based on Levels of Evidence, Centre for 
Evidence-Based Medicine [CEBM], 2011) or higher 
that investigated the effect of ABI and PRPI on pain 
and function in patients with Achilles tendinopathy.
• The literature search produced 16 possible studies 
related to the clinical question; 4 randomized control 
trials met the inclusion and exclusion criteria (Figure 
1).
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• Two of the included studies1,8 compared PRPI with 
saline injections, 1 of the studies2 compared ABI with 
tendon needling with no saline, and 1 of the studies4 
compared ABI with eccentric exercises.
• All groups in the included studies1,2,4,8 had improve-
ments in VISA-A scores; however, there were no 
significant differences found between groups.
Clinical Bottom Line
The evidence does not support the use of ABI and PRPI in 
conjunction with eccentric training to improve outcomes 
for Achilles tendinopathy. Therefore, eccentric training 
alone is sufficient to treat chronic Achilles tendinopathy.
Strength of Recommendation: In accordance 
with the 2009 CEBM levels of evidence, there is grade 
B evidence that does not support the addition of ABI or 
PRPI for the short-term treatment for chronic Achilles 
tendinopathy. Consistent level 2 evidence was found in 
the 4 included studies.
Search Strategy
Terms Used to Guide Search Strategy
• Patient/Client group: Achilles tendinopathy
• Intervention (or assessment): platelet-rich plasma 
injections OR autologous blood injections with 
eccentric training
• Comparison: saline injection OR needling AND/OR 
eccentric training
• Outcomes: pain AND function [as measured by 
Victorian Institute of Sports Assessment (VISA-A)]
Sources of Evidence Searched 




• Additional resources obtained via review of refer-
ence lists and hand search
Inclusion and Exclusion Criteria 
Inclusion Criteria
• Studies identified as level 2 evidence or higher.
• Patients diagnosed with Achilles tendinopathy
• Patients with a symptom duration >2 months
• Patients treated using PRPI or ABI
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• Use of eccentric exercises for standardized care
• Patients age 18 years or older
• Use of VISA-A as an outcome measure
• Limited to English
• Limited to humans
• Limited to publications within the last 10 years 
(2006–2015)
Exclusion Criteria
• Patients with history of Achilles rupture
• Confounding pathologies or diseases affecting the 
Achilles
Results of Search
Four relevant studies1,2,4,8 were located and categorized as 
shown in Table 1 (based on Levels of Evidence, CEBM, 
2011).
Best Evidence
The studies in Table 2 were identified as the best evidence 
and selected for inclusion in this clinically appraised 
topic (CAT). These studies were selected because they 
were graded with a level of evidence of 2, they exam-
ined the use of PRPI or ABI in the treatment of Achilles 
tendinopathy for pain and function, and the outcome of 
interest (VISA-A scores) was described.
Implications for Practice, 
Education, and Future Research
The studies included in this CAT addressed the use of ABI 
and PRPI to treat patients with Achilles tendinopathy. 
Based on this appraisal, three1,2,8 of the four1,2,4,8 studies 
found no significant difference in the primary outcome, 
VISA-A scores, in any of the experimental groups. The 
main components of the VISA-A are pain and function, 
which are the biggest complaints in patients with this type 
of pathology. However, Pearson et al4 found small short-
term symptom improvements when ABI was added to the 
standard of care. The findings of these articles indicate 
that there is no significant evidence to support using any 
level of ABI at this time. The designs of the appraised 
studies varied slightly, from eccentric strength training 
in conjunction with ultrasound-guided intratendinous 
PRPI1,8 to peritendinous ABI and the standard of care.2,4 
All 4 studies found improvement in VISA-A scores 
regardless of treatment allocation.
In the ABI performed in the included studies,2,4 3 
mL of venous blood was drawn from the patient’s ante-
cubital fossa and injected at the Achilles tendon using an 
unguided peritendinous technique. One study2 described 
using a 3-pass injection technique that involved a single 
puncture site and 1-mL injections in 3 different directions. 
The injections were done perpendicular to the tendon, 
20° superiorly and 20° inferiorly. The numerous platelet-
derived growth factors are thought to be the “active 
ingredient” of whole blood.1 The growth factors, as well 
as other cytokines present in the blood, are proposed to 
be catalysts of tissue healing, as they aid in the production 
of type I collagen in tissue of the degenerating tendon.2
In the PRPI performed in the included studies,1,8 54 
mL of blood was collected from the subject’s cubital vein. 
Six milliliters of citrate was added to the blood sample to 
prevent early clotting. The blood underwent centrifuga-
tion for 15 minutes, and the platelet rich plasma (PRP) 
was obtained from the sample. Three-tenths of a milliliter 
of 8.4% sodium bicarbonate buffer was added to the PRP 
in an effort to match the pH of the PRP with the pH of 
the tendon tissue. Four milliliters of the pH-corrected 
PRP was collected for injection. Through ultrasound-
guided injection, the PRP was injected through 3 different 
puncture locations. Five small depositions were made, 
totaling 4 mL.1,8 The platelets in the PRPI obtained from 
the whole blood release various growth factors that may 
play a role in regenerating damaged tendon tissue through 
the proliferation of new tendon cells, collagen synthesis, 
and vascularization of new tissue.8
There are many uncertainties surrounding PRPI, as 
it is a relatively new procedure. In intratendinous PRPI, 
the volume of the substance that remains within the dam-
aged tendon is unknown; some believe that the PRP may 
leak into the peritendinous space.8 This may be due, in 
part, to the increased pressure within the tendon from the 
injection. The exact composition of PRP is also unknown, 
and there is little consistency in preparation across provid-
ers.1,8 The exact amount of growth factors present in each 
PRPI is not quantified as a part of standard procedure, 
making it difficult to make concrete conclusions about its 
effectiveness.1,8 When comparing ABI with PRPI, ABIs 
are simpler and more cost-effective, as special processing 
or equipment is not needed.2 ABIs can be done without 
ultrasound guidance and require a much smaller volume 
of blood to be taken from the patient.2,4
Practitioners should use caution when suggesting 
or prescribing ABI or PRPI to patients with Achilles 
tendinopathy. All the included studies1,2,4,8 were level 2 
evidence and resulted in injection outcomes that were 
no better than those in the control groups. This suggests 
that the control was just as effective, and much more 
cost-efficient, than the injections. All 4 studies1,2,4,8 used 
Table 1 Summary of Study Designs of 
Articles Retrieved




2 Randomized  
controlled trial
4 de Vos et al1
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Alfredson eccentric calf-muscle training.3 This training 
protocol consisted of 180 eccentric heel-drop exercises 
a day for 12 weeks. Clinicians can have confidence in 
using eccentric training as the standard of care for patients 
suffering from Achilles tendinopathy until better evidence 
is found to support the use of ABI.
Tendinopathy is a response to overuse, degeneration 
of the tendon, and disorganization of collagen fibers, 
with little to no inflammation.9 The included studies 
used various ways to grade or categorize the level of 
tendinopathy in the sample population. de Vos et al1 did 
not investigate the level of tendinopathy present in their 
patients, while de Jonge et al8 examined the severity of 
the present tendinopathy based on the level of neovas-
cularization. This was scored using the modified Ohberg 
scoring system.10 This scoring system classified 0 as no 
vessels, 11 as 1 vessel (mostly anterior to the tendon), 21 
as 1 or 2 vessels throughout the tendon, 31 as 3 vessels 
throughout the tendon, or 41, which consisted of more 
than 3 vessels throughout the tendon. Bell et al2 used 
ultrasound scans to determine the level of tendinopathy 
based on a grading scale that ranged from mild to severe. 
A mild classification was awarded if the tendon displayed 
only fusiform thickening, a moderate classification if 
there were additional hypoechoic areas present, and a 
severe classification if neovessels were also present on 
Doppler scanning. Pearson et al4 classified patients with 
ultrasound scans to confirm the presence of tendinopathy. 
They also assessed the presence and degree (nil = 0, mild 
= 1, moderate = 2, or severe = 3) of neovascularization. 
Not having a consistent and universal scoring system is 
a large limiting factor in the treatment of these patients.
One major limitation of 3 of the included studies was 
the use of needling or saline injections as the control/
placebo.2,4,8 The trauma to the tendon tissue induced by 
needling likely created bleeding sufficient to induce a 
healing response in the tissue, making the needling a treat-
ment in itself and not a true control. Another limitation of 
the included studies was the use of NSAIDs by subjects 
despite being told to refrain from doing so.1,4 Each study 
had its own confounding issues. de Vos et al1 and de 
Jonge et al8 had compliance issues in both groups after 
12 weeks. Several patients also had additional treatments 
consisting of a tendon-binding band and foot orthotics. 
Four of the PRPI patients needed an additional procedure 
due to their lack of improvement.1,8 Those authors also 
wrote that increasing the peritendinous volume could 
destroy the neural and vascular growth that is causing 
the pain.1,8 Bell et al2 used a second injection, which 
could have interrupted the steady-state effect of the first 
injection, and both injections lacked ultrasound guidance. 
They also exhibited a 6% dropout rate. Pearson et al4 
allowed participants to continue low-impact exercise and 
had a 30% dropout rate. All of these limitations should 
be considered in future studies.
Suggestions for future research in all 4 studies1,2,4,8 
included a need to investigate the etiology and pathophys-
iology of Achilles tendinopathy. Knowing the cause and 
level of tendinopathy is crucial in effectively treating the 
condition. The 4 randomized controlled trials included in 
this CAT all used different ways to classify tendinopathy 
severity, since there is currently no validated classification 
for the condition on a histological level. For clinicians it 
is critical to know the source of the problem, not just the 
solution. Differentiating between tendinopathy, tendinitis, 
and tendinosis is often difficult from a clinician’s stand-
point. These conditions are very different histologically, 
but based on the limited information we can get from an 
evaluation, we often treat them the same. More research, 
and subsequent training, into diagnostic ultrasound tech-
niques (with and without Doppler sonography) could 
help us identify individualized disease severity and lead 
to better treatment outcomes. If there were more knowl-
edge surrounding a diagnosis based on histology and 
severity, we could provide a treatment more specific to 
whatever histological malady the patient is dealing with. 
Research also needs to be done to identify what happens 
at a histological level after injection therapy takes place. 
There is a discrepancy in what happens to the blood once 
it is injected, specifically, what happens at varying injec-
tion sites. Until future research and imaging illuminate 
what the dispersion and absorption rate of the injected 
substance actually is, it will remain unclear which injec-
tion site is the most appropriate. Researchers may try 
investigating an ABI- or PRPI-only intervention group 
to elucidate findings related to pain and function without 
the inclusion of confounding variables. At this point in 
time we believe that the treatment is not working because 
we are injecting patients based on a theory of what will 
happen on the microlevel without the appropriate data 
to support it. This CAT should be reviewed in 2 years or 
when additional evidence is available that may change 
the clinical bottom line for the research question posed.
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